FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals.
3 reports, 2 independent
Updated Dec 12
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval of LUMRYZ™ is contingent on sale terms, with Alkermes proposed as the buyer of Avadel Pharmaceuticals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Alkermes is integrating Avadel into its operations while discussing differentiation within the orexin agonist class.Sub-event
- FDA granted Orphan Drug Designation for LUMRYZ, a drug developed by Avadel Pharmaceuticals.Sub-event
Alkermes is proposed to buy Avadel, contingent on FDA approval of LUMRYZ™.1 source
Keep exploring
The entities involved
- FDA
-
Avadel Pharmaceuticals
specialty pharmaceutical company
Nothing else this week.
-
Alkermes
company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- prnewswire_crosscountryAvadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
- GlobeNewswireAvadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transfor
- GlobeNewswireAvadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7 DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq